The tally, one vote per house
31 of 38 research houses agree, +6 houses in 30 days. See which houses, free →
Emerging-market equities are presented as an opportunity: upward earnings revisions and cheaper valuations, led by Asia and Latin America, are seen as letting them outperform US stocks. Researchers at 31 of 38 houses hold this view, with 7 against and none mixed, and houses covering it rose by 6 over the past 30 days. The main counter-argument is that narrow leadership from a handful of AI-related stocks, shown by a rout in South Korea, leaves these markets fragile, and a minority also flags Indonesia's market reclassification and weak foreign flows.
Each house counts once: its newest view on the theme in the last 60 days. The counts are computed, not written by AI; the summary is AI-written from the houses’ views, without names.
Who the houses are
- Asset managers16
- Banks15
- Podcasts4
- Independent research firms3
Types only: names are shown to members. See who said what, free →
Houses discussing it, 12 weeks
Houses with a view in the 60 days to each week’s end. Latest: 38 houses on 3 Nov.
What the theme implies
- Emerging-market equities higher
Named in research
No fund, ETF or index has been named by at least 2 research houses for this theme yet.
Questions
What is the “EM equities” theme?
Upward earnings revisions and cheaper valuations in emerging markets, led by Asia and Latin America, let emerging-market equities outperform US stocks. It is one of 70 themes FinChiefs counts across published research from banks, asset managers, independent research firms and podcasts.
How many research houses agree?
31 of 38 research houses agree (82%), counting each house's newest view in the last 60 days: 31 agree, 0 are mixed and 7 disagree. That is +6 houses in 30 days. Members see each house by name.
Which instruments do research houses name for this theme?
No fund, ETF or index has been named by at least 2 research houses for this theme yet.
Is this investment advice?
No. Themes summarise what research houses argue. FinChiefs takes no view of its own. Instruments shown are the ones research houses name, not selected or endorsed by FinChiefs. Not investment advice. No prices are shown and no instrument pays to appear.
The Daily Digest in your inbox
Every morning, what published research argued the day before: the cross-asset and macro read in full, then every market in a line.